Profile data is unavailable for this security.
About the company
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.
- Revenue in USD (TTM)270.60m
- Net income in USD-239.24m
- Incorporated2012
- Employees545.00
- LocationAxsome Therapeutics IncOne World Trade Center, 22Nd FloorNEW YORK 10007United StatesUSA
- Phone+1 (212) 332-3241
- Fax+1 (212) 320-0245
- Websitehttps://www.axsome.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hims & Hers Health Inc | 872.00m | -23.55m | 3.37bn | 1.05k | -- | 9.77 | -- | 3.87 | -0.1131 | -0.1131 | 4.17 | 1.61 | 2.16 | 7.13 | 195.17 | 833,652.00 | -5.83 | -- | -7.02 | -- | 81.99 | -- | -2.70 | -- | 2.74 | -- | 0.00 | -- | 65.49 | -- | 64.15 | -- | -- | -- |
Simply Good Foods Co | 1.25bn | 133.28m | 3.38bn | 271.00 | 25.67 | 2.10 | 21.94 | 2.71 | 1.32 | 1.32 | 12.39 | 16.10 | 0.5943 | 6.41 | 8.49 | 4,614,288.00 | 6.33 | 3.66 | 6.58 | 3.83 | 36.59 | 38.90 | 10.66 | 6.80 | 3.46 | 7.78 | 0.1448 | 0.00 | 6.33 | 23.56 | 23.03 | 13.65 | 47.09 | -- |
Alvotech SA | 93.38m | -551.73m | 3.38bn | 999.00 | -- | -- | -- | 36.23 | -2.40 | -2.40 | 0.4109 | -3.49 | 0.105 | 2.20 | 1.39 | 93,475.48 | -62.04 | -- | -81.72 | -- | -72.26 | -- | -590.83 | -- | 0.4614 | -1.29 | 7.52 | -- | 9.84 | -- | -7.43 | -- | -- | -- |
Crinetics Pharmaceuticals Inc | 4.01m | -214.53m | 3.46bn | 290.00 | -- | 5.62 | -- | 862.80 | -3.70 | -3.70 | 0.0691 | 7.91 | 0.0081 | -- | 0.7048 | 13,837.93 | -42.39 | -42.53 | -45.71 | -45.36 | -- | -- | -5,216.32 | -5,446.39 | -- | -- | 0.00 | -- | -15.28 | 10.57 | -30.88 | -- | 34.65 | -- |
Amicus Therapeutics, Inc. | 399.36m | -151.58m | 3.50bn | 517.00 | -- | 21.74 | -- | 8.77 | -0.5148 | -0.5148 | 1.35 | 0.5456 | 0.5318 | 0.8939 | 5.19 | 772,448.80 | -20.18 | -30.65 | -25.36 | -36.55 | 90.65 | 88.94 | -37.96 | -86.10 | 2.52 | -1.76 | 0.7077 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
Arrowhead Pharmaceuticals Inc | 181.74m | -296.81m | 3.56bn | 525.00 | -- | 19.23 | -- | 19.57 | -2.77 | -2.77 | 1.69 | 1.49 | 0.2395 | -- | -- | 346,171.40 | -39.91 | -20.02 | -46.61 | -24.65 | -- | -- | -166.63 | -61.79 | -- | -55.19 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
Fortrea Holdings Inc | 3.11bn | -3.40m | 3.58bn | 18.00k | -- | 2.05 | 38.53 | 1.15 | -0.0379 | -0.0379 | 35.03 | 19.58 | -- | -- | -- | 172,722.20 | -- | -- | -- | -- | 16.74 | -- | -0.1094 | -- | -- | 1.27 | 0.478 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
Immunitybio Inc | 622.00k | -583.20m | 3.68bn | 628.00 | -- | -- | -- | 5,916.04 | -1.13 | -1.13 | 0.0012 | -0.875 | 0.0014 | -- | 0.246 | 990.45 | -134.71 | -112.76 | -377.77 | -316.07 | -- | -- | -93,866.88 | -37,700.74 | -- | -2.08 | 3.32 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
SpringWorks Therapeutics Inc | 5.45m | -325.10m | 3.70bn | 305.00 | -- | 5.88 | -- | 678.67 | -5.14 | -5.14 | 0.0862 | 8.52 | 0.008 | -- | -- | 17,859.02 | -47.95 | -36.97 | -53.00 | -39.49 | 92.25 | -- | -5,968.50 | -2,176.46 | 6.37 | -- | 0.00 | -- | -- | -- | -17.19 | -- | 90.68 | -- |
Arcellx Inc | 110.32m | -70.69m | 3.72bn | 130.00 | -- | 7.59 | -- | 33.72 | -1.49 | -1.49 | 2.30 | 9.28 | 0.1937 | -- | -- | 848,607.70 | -12.41 | -38.82 | -14.67 | -45.41 | -- | -- | -64.08 | -339.38 | -- | -- | 0.0749 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
Axsome Therapeutics Inc | 270.60m | -239.24m | 3.75bn | 545.00 | -- | 19.63 | -- | 13.86 | -5.20 | -5.20 | 5.96 | 4.03 | 0.5885 | 2.68 | 4.08 | 496,513.80 | -52.02 | -64.55 | -69.92 | -82.23 | 90.37 | -- | -88.41 | -227.05 | 3.52 | -35.93 | 0.4825 | -- | 440.80 | -- | -27.84 | -- | 77.86 | -- |
Ultragenyx Pharmaceutical Inc | 434.25m | -606.64m | 3.85bn | 1.28k | -- | 13.99 | -- | 8.88 | -8.33 | -8.33 | 5.91 | 3.35 | 0.286 | 1.49 | 7.63 | 340,320.50 | -39.96 | -33.35 | -48.63 | -38.30 | 89.59 | 93.13 | -139.70 | -154.71 | 2.49 | -- | 0.00 | -- | 19.52 | 53.18 | 14.25 | -- | 62.91 | -- |
Apogee Therapeutics Inc | 0.00 | -83.99m | 3.91bn | 91.00 | -- | 8.67 | -- | -- | -1.74 | -1.74 | 0.00 | 7.86 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
Iovance Biotherapeutics Inc | 1.19m | -444.04m | 3.94bn | 557.00 | -- | 6.18 | -- | 3,312.22 | -1.89 | -1.89 | 0.0051 | 2.28 | 0.0017 | -- | -- | 2,134.65 | -61.49 | -51.47 | -71.47 | -57.56 | -804.54 | -- | -37,345.42 | -137,873.80 | 2.70 | -- | 0.0017 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
Insmed Inc | 305.21m | -749.57m | 4.06bn | 912.00 | -- | -- | -- | 13.29 | -5.35 | -5.35 | 2.17 | -2.24 | 0.2044 | 0.8562 | 8.61 | 334,657.90 | -50.20 | -40.96 | -58.32 | -46.88 | 78.52 | 77.99 | -245.59 | -212.92 | 3.75 | -17.21 | 1.39 | -- | 24.39 | 98.78 | -55.66 | -- | -2.15 | -- |
Holder | Shares | % Held |
---|---|---|
RTW Investments LPas of 31 Dec 2023 | 4.49m | 9.48% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 3.60m | 7.59% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 2.80m | 5.92% |
Fairmount Funds Management LLCas of 31 Dec 2023 | 2.36m | 4.98% |
BVF Partners LPas of 31 Dec 2023 | 1.98m | 4.18% |
Perceptive Advisors LLCas of 31 Dec 2023 | 1.04m | 2.19% |
Deep Track Capital LPas of 31 Dec 2023 | 1.00m | 2.11% |
RA Capital Management LPas of 31 Dec 2023 | 1.00m | 2.11% |
Citadel Advisors LLCas of 31 Dec 2023 | 947.67k | 2.00% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 924.19k | 1.95% |